Background: A reflex cough is often observed after an intravenous (IV) bolus of remifentanil. Since ketamine was reported to be effective in modulating the cough reflex, this prospective, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy of pretreatment with ketamine on remifentanil-induced cough.
INTRODUCTION
Remifentanil has favorable pharmacokinetic properties with rapid onset and offset of action, which makes it appropriate adjunct during anesthesia induction to provide cardiovascular stability and intense analgesia. However, a small dose of intravenous remifentanil elicits cough, as any other opioid of fentanyl series [1] . Based on previous studies, the incidence of remifentanil-induced cough was higher than that of fentanyl-induced cough [1, 2] . The prevention of opioid-induced cough has an important clinical implication because opioid associated cough can be severe enough to cause multiple conjunctival and periorbital petechia, which may have resulted form increased intracranial, intra-ocular, and intra-abdominal pressure [3, 4] .
The increase in intraoculr or intracranial pressure can be devastating to patients with glaucoma or a space occupying lesion in the brain. The need to reduce cough during opioid injection has encouraged many different approaches using local anesthetics, ketamine, selective β-agonist and many others with varying results [1, [5] [6] [7] [8] [9] .
N-methyl-D-aspartate (NMDA) receptor was reported to play a critical role in the modulation of the cough reflex [10] .
Therefore, the purpose of this study was to evaluate the efficacy of pretreatment with ketamine, an NMDA receptor antagonist, on remifentanil-induced cough.
MATERIALS AND METHODS
This study was approved by the institutional review board and written informed consent for the study was obtained from Assisted mask ventilation with oxygen was applied if desaturation was observed (SpO2 ＜ 90%). The incidences of apnea, truncal rigidity, and psychomimetic symptoms were also recorded. Apnea was defined as a pause in breathing for more than 15 seconds and truncal rigidity as increased large trunk muscle tone, which renders facemask ventilation difficult or impossible. Any unpleasant symptoms including dissociative feelings ("elevator" effect), alertness disturbances (somnolence or insomnia) or sensory changes (taste changes, numbness, tingling, hot, cold) were considered as psychomimetic symptoms.
Mean arterial pressure (MAP), heart rate (HR), and SpO2 were recorded on arrival in the operating room (baseline) and 1 min after remifentanil infusion. Authors hypothesized that the incidence of cough during remifentanil injection would be reduced with pretreatment of an NMDA antagonist, ketamine. Therefore, the primary outcome was the reduction of the incidence of cough and the secondary outcome was the severity of cough.
Considering the incidence of remifentanil-induced cough was 27% [1] and assuming a decrease in the incidence of cough to half of control after ketamine treatment, this study required at least 152 patients per group at the 5% level of significance and 80% power of test. Considering 5% drop out rate, 320 patients were randomized in this study.
Statistical analyses were performed with the statistical package (SPSS 13.0 for windows, SPSS Inc, Chicago, IL, USA).
Data are presented as mean ± SD or number of patients.
Patients' characteristics, the difference of onset time to cough and hemodynamic variables between groups were compared with Student's t-test. Incidence of coughing was analyzed with chi-square test. A P value ＜ 0.05 was considered statistically significant.
RESULTS
Four patients in ketamine group and 6 patients in saline group did not complete the study due to intravenous line obstruction. There was no significant difference in patient characteristics between the two groups ( Table 1 ). The overall incidence of cough was significantly higher in the saline group (43/154 patients; 0.28, 95% CI 0.21, 0.36) than that in the ketamine group (18/156 patients; 0.12, 95% CI 0.07, 0.18) (P ＜ 0.001). However, there was no significant difference in the severity and the onset time of cough between the groups. In the ketamine group, 18 patients had cough and 10, 4, and 4 of those patients had mild, moderate, and severe cough, respectively. This was similar to the saline group in which 23, Values are mean ± SD. MAP: mean arterial blood pressure, HR: heart rate. 12, and 8 of 43 patients who coughed had mild, moderate, and severe cough, respectively (Table 2) . No patient complained psycomimetic symptoms in the ketamine group during anesthesia induction.
Hemodynamic data were lost in 22 and 14 patients in ketamine and saline group, respectively. MAP and HR during anesthesia induction are listed in Table 3 . MAP at 1 min after remifentanil infusion in saline group was significantly decreased from the baseline value. In the both groups, HR was significantly increased significantly 1 min after remifentanil infusion compared with baseline. None of the patients suffered from hypoxemia, desaturation, apnea, truncal rigidity, or other adverse effects.
DISCUSSION
This study demonstrated that when remifentanil was administered at target effect-site concentration of 5 ng/ml, pretreatment of intravenous ketamine 0.1 mg/kg reduced the incidence of remifentanil-induced cough from 27.9% to 11.5% (P ＜ 0.001).
However, its severity and onset time was unaffected (P ＞ 0.05).
Several reports using different drugs have been recently published to prevent the opioid-induced cough [1, [5] [6] [7] [8] [9] . Most of them were on the fentanyl-induced cough. Although various mechanisms responsible for opioid-induced cough have been postulated, the exact mechanism is still unclear. Opioid could inhibit central sympathetic outflow, therefore activating the vagus nerve. This enhancement of vagal activity was reported as a possible cause of cough and reflex bronchoconstriction [7, 11, 12] . Other possible mechanisms postulated as the cause of opioid-induced cough include pulmonary chemoreflex, which is mediated by either rapidly adapting irritant receptors or vagal C-fiber receptors located in proximity to pulmonary vessels [13, 14] , and the trigger stimulus and bronchial hyperirritability theory [7, 12] .
Ketamine is a noncompetitive NMDA receptor antagonist and NMDA receptor was suggested to be involved in regulation of cough reflex [10] . Experimental studies have demonstrated that remifentanil activated NMDA receptor but fentanyl did not [15, 16] . The incidence of remifentanil-induced cough in this study was higher than that of fentanyl-induced cough (27.9% vs. 8% respectively) [2] . This higher incidence of cough with remifentanil may be explained by the difference in the stimulation of NMDA receptors. Ketamine may attenuate reflex bronchoconstriction or cough through the blockade of NMDA receptor activation, which result in the direct or indirect bronchodilating effects on airway smooth muscle [3, 17] .
Bongianni et al [18] reported in anesthetized rabbits that microinjection of NMDA receptor antagonists into the caudal part of ventral respiratory group suppressed the inspiratory and expiratory components of cough reflex. Previous study using small dose lidocaine (0.5 mg/kg) reported that there was a significant reduction in the incidence of cough (absolute risk reduction, 12.4%; relative risk reduction, 44.9%) [1] . In this study using 0.1 mg/kg of ketamine, the risk reduction was greater than the study with lidocaine since there was significant reduction in the incidence rate of cough from 27.9% to 11.5% (absolute risk reduction, 16.4%; relative risk reduction, 60.4%). Ketamine was administered 1 min before remifentanil infusion because ketamine has the rapid onset of action with peak concentration occurring within 1 min after IV administration. The dose of ketamine (0.1 mg/kg) in this study was based on a previous study by Yeh et al (0.15 mg/kg) [5] .
The dose was reduced to decrease the side-effects of ketamine.
As for the hemodynamic effect of ketamine during anesthesia induction, there were significant differences in MAP and SpO2, but it was clinically insignificant because no patients had showed a MAP above 120 mm Hg or SpO2 ＜ 90%.
Furthermore, MAP in ketamine group did not change 1 min after remifentanil infusion, whereas that in the saline group was significantly decreased. These results are consistent with a previous study by Koo et al [19] .
In conclusion, administration of IV ketamine 0.1 mg/kg one minute before remifentanil was effective in suppressing remifentanil-induced cough without affecting the severity and onset time.
